AZN vs RCUS
AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline. RCUS: A clinical-stage biopharmaceutical company focused on discovering and developing innovative, small-molecule and antibody-based oncology therapies through a robust pipeline and strategic collaborations.
Side-by-side fundamentals
| Metric | AZN | RCUS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $158.78 | $23.83 | |
| Market cap | $181.5B | $3.0B | |
| P/E as of 2026-09-03 | 23.44 | n/a | |
| Net margin FY2025, SEC XBRL | +17.4% | -1069.7% | AZN higher |
| Gross margin FY2025, SEC XBRL | +81.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +23.4% | -1169.7% | AZN higher |
| ROE FY2025, SEC XBRL | +21.0% | -55.9% | AZN higher |
| ROA FY2025, SEC XBRL | +9.0% | -31.0% | AZN higher |
| Debt / equity as of 2026-09-03 | 0.64 | 0.22 | RCUS lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.6% | -50.0% | AZN higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | -4.6% | AZN higher |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.34 | 1.41 | |
| 1-year return as of 2026-10-08 close | -7.0% | +58.3% | RCUS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.